Therapeutic Cyclopentanes for Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma and ocular hypertension lack effective solutions, and prostaglandin EP2 selective agonists have various medical uses but require more targeted and efficient compounds for these conditions.
Innovation Solution
Development of specific compounds, including their pharmaceutically acceptable salts and prodrugs, which act as selective EP2 agonists to treat glaucoma and ocular hypertension, with structures that can be administered topically or systemically, potentially combined with other drugs for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prostaglandin EP2 selective agonists are used to treat glaucoma and ocular hypertension, then therapeutic effectiveness is improved, but current treatments lack targeted efficiency
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural modifications at particular positions of the prostaglandin molecule. The cyclopentane ring with specific substituents at defined positions creates localized structural features that enhance EP2 receptor selectivity, thereby improving targeted efficiency while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, positions, and stereochemistry of the cyclopentane ring structure. These parameter modifications optimize the compound's affinity and selectivity for the EP2 receptor, resolving the contradiction between general effectiveness and targeted efficiency.
2Measurement precision
If selective EP2 agonist compounds are developed with specific structures, then targeted treatment capability is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the prostaglandin molecule into distinct functional segments: the cyclopentane ring core, specific substituents at defined positions, and stereochemical configurations. This segmented approach allows each component to contribute specifically to EP2 selectivity, improving targeted treatment capability while managing overall molecular complexity through modular design.
Solution Approach 2:
The patent utilizes universality by designing a core cyclopentane structure that serves multiple functions: providing structural stability, enabling specific receptor binding, and allowing for various substituent variations. This multi-functional core structure achieves high targeted treatment capability without proportionally increasing complexity, as the same basic framework supports multiple therapeutic optimizations.
Data Source
AI summary
Therapeutic prostaglandin compounds are disclosed herein.